PAH News

July 9, 2018July 12, 2018

Protein Involved in PAH Development a Potential Therapeutic Target, Study Suggests

News, PAH News

A certain protein found on white blood cells, which plays a role in causing pulmonary arterial hypertension (PAH), may be a potential new therapeutic target, a study in mice ... Read more

June 29, 2018July 6, 2018

Roivant Launches Altavant Sciences, a New Company Developing PAH Therapy RVT-1201

News, PAH News

Roivant recently announced the launch of two new business units, Roivant Pharma and Roivant Health, as well as the creation of Altavant Sciences, a company that will focus on developing new ... Read more

June 27, 2018June 27, 2018

PH Patient Registries Across Europe Should Be Combined for Better Data, Study Suggests

CTEPH News, News, PAH News

Larger pulmonary hypertension (PH) registries are needed to advance knowledge about this disease and improve patient care, a new study emphasizes. The report outlines data from a Latvian PH ... Read more

June 21, 2018June 25, 2018

Apelin Improves Pulmonary and Cardiac Functions in PAH Patients, Clinical Trial Shows

News, PAH News

Apelin, a peptide naturally produced in the body, reduces resistance in the pulmonary vascular system (blood vessels) and improves cardiac function in patients with pulmonary arterial hypertension (PAH), results ... Read more

June 20, 2018June 27, 2018

PAH-Specific Therapies Benefit PAH Patients with Congenital Heart Disease, Review Study Shows

News, PAH News

Clinical trials testing pulmonary arterial hypertension (PAH) therapies show that PAH patients who also have congenital heart disease (CHD) can also benefit from these therapies, improving exercise capacity, blood ... Read more

June 18, 2018June 22, 2018

Cancer Marker NEDD9 Could Be a Therapeutic Target for PAH, Study Suggests

News, PAH News

A cancer marker called NEDD9 is a critical mediator of pulmonary arterial hypertension (PAH) and could be a therapeutic target, according to new research. The study, “NEDD9 targets COL3A1 ... Read more

June 15, 2018June 15, 2018

PAH Greatly Impairs Survival of Scleroderma Patients in First Years After PAH Diagnosis

News, PAH News

Scleroderma patients diagnosed with pulmonary arterial hypertension (PAH) are at a high risk of PAH-related death, especially in the four years after the PAH diagnosis, a study shows. Also, being ... Read more

June 14, 2018June 14, 2018

Canada Expands Public Health Coverage for PAH Therapy Uptravi

News, PAH News

Five Canadian provinces, Alberta, Ontario, Saskatchewan, Manitoba, and Newfoundland and Labrador, have approved public health insurance coverage for Uptravi (selexipag), a pulmonary arterial hypertension (PAH) therapy developed by Actelion. ... Read more

June 11, 2018June 11, 2018

Treprostinil Delivered Using Technosphere Portable Inhaler Seen as Safe in Early Clinical Trial

News, PAH News

A Phase 1 clinical trial (NCT03464864) found that treprostinil can be safely delivered at varying doses using Technosphere, a novel inhalation device, MannKind, the device’s developer, announced. Treprostinil — a vasodilator ... Read more

June 7, 2018June 7, 2018

Denovo Working with Stanford to Test EB102 as ‘Repurposed’ Potential Treatment for PAH and Emphysema

News, PAH News

Denovo Biopharma recently entered an exclusive global license agreement with Stanford University School of Medicine to further develop and market its lead compound, DB102 (formerly called enzastaurin), as a ... Read more

Pin It on Pinterest